

Pembrolizumab KEYNOTE-177

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Less serious adverse events observed



Other adjustments



Long term plateau in the PFS curve



Pembrolizumab KEYNOTE-177

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers  
 Therapeutic Indication: First-line treatment of adults with MSI-H or dMMR mCRC  
 Experimental Arm: Pembrolizumab  
 Control Arm: ChT (5-fluorouracil-based therapy with or without bevacizumab or cetuximab)

